In silico vaccine design and epitope mapping of New Delhi metallo-beta-lactamase (NDM): an immunoinformatics approach

Background: Antibiotic resistance is a global health crisis. The adage that “prevention is better than cure” is especially true regarding antibiotic resistance because the resistance appears and spreads much faster than the production of new antibiotics. Vaccination is an important strategy to fight...

Full description

Bibliographic Details
Main Authors: Abiri, R. (Author), Alvandi, A. (Author), Fathollahi, A. (Author), Fathollahi, M. (Author), Moradi, J. (Author), Motamedi, H. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2021
Subjects:
Online Access:View Fulltext in Publisher
LEADER 03937nam a2200637Ia 4500
001 10.1186-s12859-021-04378-z
008 220427s2021 CNT 000 0 und d
020 |a 14712105 (ISSN) 
245 1 0 |a In silico vaccine design and epitope mapping of New Delhi metallo-beta-lactamase (NDM): an immunoinformatics approach 
260 0 |b BioMed Central Ltd  |c 2021 
856 |z View Fulltext in Publisher  |u https://doi.org/10.1186/s12859-021-04378-z 
520 3 |a Background: Antibiotic resistance is a global health crisis. The adage that “prevention is better than cure” is especially true regarding antibiotic resistance because the resistance appears and spreads much faster than the production of new antibiotics. Vaccination is an important strategy to fight infectious agents; however, this strategy has not attracted sufficient attention in antibiotic resistance prevention. New Delhi metallo-beta-lactamase (NDM) confers resistance to many beta-lactamases, including important carbapenems like imipenem. Our goal in this study is to use an immunoinformatics approach to develop a vaccine that can elicit strong and specific immune responses against NDMs that prevent the development of antibiotic-resistant bacteria. Results: In this study, 2194 NDM sequences were aligned to obtain a conserved sequence. One continuous B cell epitope and three T cell CD4+ epitopes were selected from NDMs conserved sequence. Epitope conservancy for B cell and HLA-DR, HLA-DQ, and HLA-DP epitopes was 100.00%, 99.82%, 99.41%, and 99.86%, respectively, and population coverage of MHC II epitopes for the world was 99.91%. Permutation of the four epitope fragments resulted in 24 different peptides, of which 6 peptides were selected after toxicity, allergenicity, and antigenicity assessment. After primary vaccine design, only one vaccine sequence with the highest similarity with discontinuous B cell epitope in NDMs was selected. The final vaccine can bind to various Toll-like receptors (TLRs). The prediction implied that the vaccine would be stable with a good half-life. An immune simulation performed by the C-IMMSIM server predicted that two doses of vaccine injection can induce a strong immune response to NDMs. Finally, the GC-Content of the vaccine was designed very similar to E. coli K12. Conclusions: In this study, immunoinformatics strategies were used to design a vaccine against different NDM variants that could produce an effective immune response against this antibiotic-resistant factor. © 2021, The Author(s). 
650 0 4 |a Antibiotics 
650 0 4 |a Antibiotics resistance 
650 0 4 |a B cells 
650 0 4 |a beta lactamase 
650 0 4 |a beta-lactamase NDM-1 
650 0 4 |a beta-Lactamases 
650 0 4 |a biology 
650 0 4 |a Computational Biology 
650 0 4 |a computer simulation 
650 0 4 |a Computer Simulation 
650 0 4 |a Cytology 
650 0 4 |a epitope 
650 0 4 |a epitope mapping 
650 0 4 |a Epitope Mapping 
650 0 4 |a Epitopes 
650 0 4 |a Epitopes, T-Lymphocyte 
650 0 4 |a Escherichia coli 
650 0 4 |a Escherichia coli 
650 0 4 |a Escherichia coli 
650 0 4 |a genetics 
650 0 4 |a Immune response 
650 0 4 |a Immune system 
650 0 4 |a Immunoinformatic 
650 0 4 |a Immunoinformatics 
650 0 4 |a In silico 
650 0 4 |a In-silico 
650 0 4 |a Lactamases 
650 0 4 |a Multi epitope 
650 0 4 |a Multi-epitope based vaccine 
650 0 4 |a Multi-epitope based vaccine 
650 0 4 |a New delhi metallo-beta-lactamase 
650 0 4 |a New Delhi metallo-beta-lactamase 
650 0 4 |a Peptides 
650 0 4 |a T-cells 
650 0 4 |a Vaccine design 
650 0 4 |a Vaccine design 
650 0 4 |a Vaccines 
700 1 |a Abiri, R.  |e author 
700 1 |a Alvandi, A.  |e author 
700 1 |a Fathollahi, A.  |e author 
700 1 |a Fathollahi, M.  |e author 
700 1 |a Moradi, J.  |e author 
700 1 |a Motamedi, H.  |e author 
773 |t BMC Bioinformatics